http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/190 2026-04-05T22:45:10Z 2026-04-05T22:45:10Z 林孟謙 Meng-Chien Lin http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/95016 2024-08-26T16:16:14Z 2024-01-01T00:00:00Z

標題: 開發尋找慢性腎臟病潛在治療標的之策略; Developing a Strategy to Identify Potential Therapeutic Targets for Chronic Kidney Disease 作者: 林孟謙; Meng-Chien Lin 摘要: 慢性腎臟病(CKD)是世界上最迫切且尚未解決的健康問題之一。它也成為亞洲許多人的夢魘，尤其是俗稱「腎臟透析王國」的台灣。目前慢性腎臟病的治療方法有血液透析、腹膜透析、藥物治療等。這些治療方法僅能幫助減輕不適或延緩病程，然而，它們卻無法完全遏止慢性腎臟病的進展。因此，確定慢性腎臟病新的治療標靶是必要的，並且可視為前景廣闊。本文的研究目的是確定慢性腎臟病的新治療標靶。首先，我們進行了文獻綜述，以尋找可能成為慢性腎臟病新標靶的候選基因。接下來，我們使用GEO資料庫評估了這些基因在健康和纖維化腎臟上的基因表現量。我們發現NCK Adaptor Protein 2 (NCK2)，酪胺酸激酶(NCK)家族非催化區的成員之一，在纖維化腎臟中高表達，指示它有可能成為慢性腎臟病的新標靶。經過實驗驗證，結果推測NCK2的過度表現會輕微抑制人類近端腎小管細胞(HK-2)的細胞活力。這項觀察結果可能會導致未來更進一步的機制研究和藥物開發，並嘗試為慢性腎臟病患者提供全新的治療選擇。透過這項結果，人們可以預期改善慢性腎臟病患者的健康和生活品質。; Chronic kidney disease (CKD) is one of the most urgent and unresolved health issues in the world. It has also been a plague for many people in Asia, especially Taiwan, commonly referred to as the "Kingdom of Kidney Dialysis." CKD is now treated with hemodialysis, peritoneal dialysis, medication management. These therapies can only help to lessen discomfort or delay the course of the illness; they cannot, however, halt CKD progression. Thus, identification of new therapeutic targets for CKD will be required and promising. The aim of the study is to identify new intervention targets for CKD treatment. First, we performed a literature review to identify candidate genes that potentially could be new therapeutic targets of CKD. Next, we evaluated gene expression levels of these genes on healthy and fibrotic kidneys by using the GEO database. We found that NCK adaptor protein 2 (NCK2), a member of the Non-catalytic region of tyrosine kinase (NCK) family, was highly expressed in the fibrotic kidneys, suggesting it could be a new therapeutic target for CKD. After the experimental verification, the result speculated that overexpression of NCK2 slightly inhibited the viability of human proximal tubular cells (HK-2). This observation may lead to future mechanistic study and drug development and an attempt to give novel treatment options for patients with CKD. With this outcome, people can anticipate to improve the health and quality of life of those who suffer from CKD.

2024-01-01T00:00:00Z Chia-Hua Chen 陳嘉華 http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80837 2022-11-24T03:18:31Z 2021-01-01T00:00:00Z

標題: 透過乳源穩定性評估來降低臺灣生產乳製品過程中的浪費和成本; Reduce production waste and cost in manufacturing of dairy products in Taiwan via milk source stability evaluation 作者: Chia-Hua Chen; 陳嘉華 摘要: 台灣乳業的困境是必然要解決的重要課題。隨著對乳製品的需求增加，提高生乳的產量來補足需求是必要的。從國外進口乳製品彌補了需求缺口。進口乳製品中，乳粉占比最高。不同批次的乳粉安定性可能不一致。在乳製品加工過程中，製程的條件差異可會導致乳粉沉澱。它也因此增加了生產成本。針對這個問題，安定的乳粉有減低沉澱發生的可能。透過淘汰掉不合適的乳粉等級來減少沉澱的情形。本研究將建立一個簡單有效的穩定性試驗。二十一個全脂乳粉樣品回溶成15% (w/v) 乳粉溶液後，經過75% 和80%酒精測試與熱壓力測試，用以評估牛乳蛋白質。二十一個樣品在顯微鏡下觀察後拍攝並記錄。酒精試驗後離心並以絮凝乳粉重占溶液總重來量化沉澱並以百分率表示。熱壓力測試後以下降酸鹼值量化並以百分率表示。透過這個圖表來設定篩選安定乳粉標準。長遠來看，一旦乳粉安定性測試被乳品製造商廣泛採用，將有助於減少生產浪費，提高整體產品質量，為全球乳品業的未來發展貢獻一份心力。

2021-01-01T00:00:00Z Hsi-En Lee 李錫恩 http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84910 2023-03-19T22:32:14Z 2022-01-01T00:00:00Z

標題: 論歐洲有柄橡木和歐洲山毛櫸的發芽期的地方生物多樣性依賴性轉變：比利時北部地區的物候學研究; Local Biodiversity-Dependent Shifting of Budburst Timing of Pedunculate Oak (Quercus robur) and European Beech (Fagus sylvatica) in Northern Belgium. 作者: Hsi-En Lee; 李錫恩 摘要: 迅速的氣候變化極有可能提高極端天氣事件的發生率。小規模的農民在全球糧食生產系統中至關重要，但他們特別容易受到氣候變化帶來的威脅。 2020年，聯合國糧食及農業組織（糧農組織）發表了一份關於糧食安全的報告。在該報告中，糧農組織強調要增強小農戶糧食生產系統的適應性。這份報告中提到的一種適應性方法被稱為 '混農林業'。過去和現在的證據表明，農林業在增加農作物年產量的同時，也提供了一些環境效益。然而，植物的種間競爭會意外地影響植物物候的可塑性。 為了了解生物多樣性是否會導致多年生樹木春季落葉的時間發生轉變。我參加了安特衛普大學植物和生態系統（PLECO）研究小組的一個物候學研究項目。在這個項目中，我們比較了FORBIO實驗林中Quercus Robur和Fagus Sylvatica的單品種地塊與Zedelgem和Brasschaat的Peerdsbos公園的多品種地塊。我們調查了芽苞的開始，並進一步描述了這一生理事件與氣候和非氣候因素之間的關係，這些因素對預測不同物種的芽苞的動態重要性。這項研究旨在提高我們在快速氣候變化下預測未來植被和養分動態的能力，希望應用這種方法來評估農林間作系統中物種間競爭的潛在後果。; The rapid climate change is strongly possible to raise the occurrence of extreme weather events. Small-scale farmers are vital in the global food production system, but they are extra vulnerable to threats brought by climate change. In 2020, the Food and Agriculture Organization of the United Nations (FAO) published one report on food security. In that report, FAO emphasized enhancing resilience in smallholder farmers' food-producing system. One adaptive method mentioned in this report is called 'Agroforestry'. Past and present evidence indicates that agroforestry offers several environmental benefits while increasing the annual yield of crops. However, inter-species competition of plants can unexpectedly influence the plasticity of plants' phenological events. To understand whether biodiversity can cause a shifting in the onset of perennial trees' spring leaf-out. I participated in a phenological research project in the research group Plants and Ecosystems (PLECO), University of Antwerp. In this project, we compared mono-species plots of Quercus Robur and Fagus Sylvatica in the FORBIO experimental forest with multispecies sites in Zedelgem and the Peerdsbos park in Brasschaat. We investigated the onset of budburst and further characterized the relationship of this physiological event between climatic and non-climatic factors concerning their dynamic importance for predicting budburst in different species. This study aims to increase our capability to predict future vegetation and nutrient dynamics under rapid climate change, hoping to apply this method to assess the potential consequence of inter-species competition in the agroforestry intercropping system.

2022-01-01T00:00:00Z 張靖瀅 Ching-Ying Chang http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89788 2023-11-10T09:10:56Z 2023-01-01T00:00:00Z

標題: 藥品可及性的跨大陸比較分析; A cross-continental comparative analysis of the drug access system 作者: 張靖瀅; Ching-Ying Chang 摘要: 藥品可及性延遲是藥證取得、藥品定價、藥品納入健保延遲所得到的結果，這 會對個人的健康和財政狀況造成負面影響。本文利用各國衛生主管機關公開的資 料，比較分析北美、歐洲、亞洲等不同大陸間的藥品可及性、新藥申請、藥品定 價等過程及系統，並透過 Cyramza (Ramucirumab) 和 Zejula (Niraparib)這兩個藥 品的案例分析，來強化論述。此分析總結出藥證取得延遲通常各國相似，但是藥 品納入健保卻因為各國投入健保的預算及當地未滿足醫療需求不同，而造成相當 大的延遲差異，總體來說，這個比較分析報告提供了不同大陸間製藥產業的法規 和定價系統有價值的洞見，以期待能增加藥品可及性。; Drug access delays, including market authorization, pricing, and reimbursement delays, can significantly impact individuals' health and wealth. The study analyzes drug access, new drug approval processes, and pricing systems in several continents, including North America, Europe, and Asia, based on data disclosed by their regulatory authorities. The analysis relies on two case studies (Cyramza (Ramucirumab) and Zejula (Niraparib)) to strengthen the finding. This report finds that the market authorization waiting time is usually similar within countries. However, reimbursement delays can vary significantly because of the healthcare budget and national unmet medical needs differences. Overall, the comparative analysis provides valuable insights into the pharmaceutical industry's regulatory frameworks and pricing mechanisms in different regions, emphasizing the need for ongoing policy development to improve drug access and affordability globally.

2023-01-01T00:00:00Z